annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
The Biology and Treatment of Wilms Tumor
Location: S504
CME credit: 1.25
Track(s): Pediatric Oncology; Tumor Biology
Jeffrey Dome, MD—Chair
Children’s National Medical Center
Wilms Tumor: Unsettled Questions and Controversies
Nazneen Rahman, PhD, FRCP
The Royal Marsden Institue of Cancer Research
New Developments in Wilms Tumor Genetics
Elizabeth Perlman, MD
Northwestern University
Gene Expression Arrays: What Have They Taught Us about Wilms Tumor?
Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or
How Much Therapy?
Location: E354b
CME credit: 1.25
Track(s): Genitourinary Cancer; Patient and Survivor Care
Christian K. Kollmannsberger, MD—Chair
British Columbia Cancer Agency
Management Options for Early-stage Seminoma and Nonseminoma
David Peter Wood, MD
University of Michigan
Is RPLND Still Relevant?
George J. Bosl, MD
Memorial Sloan-Kettering Cancer Center
Toxicity and Survivorship in Testicular Cancer Survivors: Should It Modify What I Do?
Translocation-specific Sarcomas: Can Molecular Targets Translate to
Therapeutics?
Location: S406 (Vista Room)
CME credit: 1.25
Track(s): Sarcoma; Pediatric Oncology
Lee J. Helman, MD—Chair
National Institutes of Health/National Cancer Institute
IGF1R Targeting of Translocation-associated Sarcomas
Marc Ladanyi, MD
Memorial Sloan-Kettering Cancer Center
Target Genes of Chimeric Transcription Factors in Pediatric Sarcomas: A Source of Potential
Therapeutic Targets
Jeffrey Toretsky, MD
Georgetown University
Targeting Protein Products of Sarcoma-specific Translocations with Small Molecules
296